key: cord-0932279-d8j1pkz4
authors: Caselli, D.; Chironna, M.; Loconsole, D.; Aricò, M.
title: Response to ‘No evidence of SARS‐CoV‐2 infection by polymerase chain reaction or serology in children with pseudo‐chilblain’. Reply from the authors
date: 2020-09-25
journal: Br J Dermatol
DOI: 10.1111/bjd.19563
sha: 16e7de5c267efd795816fb7cd3f739b2ac73a650
doc_id: 932279
cord_uid: d8j1pkz4

Dear Editor, Recalcati et al. conclude that chilblain‐like lesions (CLLs) are part of the spectrum of COVID‐19 based on reports of SARS‐CoV‐2 in endothelial cells of skin biopsies assessed by immunohistochemistry and electron microscopy (EM).(1) Nevertheless, the conclusion does not seem to be adequately supported by the data. Recalcati et al. expand their previously reported case series to include 32 patients with CLLs. In 21 of 32 cases, no nasopharyngeal swab (NPS) was tested for SARS‐CoV‐2. Two of 11 patients subjected to molecular testing were positive for SARS‐CoV‐2, but no serological test was performed to verify the seroconversion. Three patients tested positive for IgM and negative for IgG antibodies without any confirmation of infection through NPS.

To support the conclusion that CLLs are associated with COVID-19, Recalcati et al. cite

Colmenero et al. However, a substantial limitation of that study was the lack of any serological assay performed in their patients. The use of EM morphology is certainly of interest but cannot be taken as a completely satisfactory state-of-the-art assessment of a novel virus. Detection of SARS-CoV-2 using molecular methods in biopsies would certainly offer much more stringent evidence of the presence of the virus in the lesional tissue.

SARS-CoV-2 endothelial infection causes COVID-19 chilblains: histopathological, immunohistochemical and ultrastructural study of seven paediatric cases

Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study

Diagnostic performance of seven rapid

IgG/IgM antibody tests and the Euroimmun IgA/IgG ELISA in COVID-19 patients

Conflicts of interest: the authors declare they have no conflicts of interest